Key clinical point: Compared with placebo, teriflunomide increases the likelihood that a patient with relapsing-remitting MS will achieve no evidence of disease activity (NEDA).
Major finding: The win ratio of achieving NEDA is 1.33 in favor of teriflunomide.
Study details: An analysis of the TEMSO study, which included 722 patients with relapsing-remitting MS.
Disclosures: The TEMSO study was funded by Sanofi. Several of the investigators received compensation from Sanofi.
Edwards KR et al. ACTRIMS 2020, Abstract P036.